Fig. 1
From: MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
The predictive value of MED12 mutation in immunotherapy of pan-cancer. A Kaplan–Meier survival analysis comparing PFS between MED12-Mut and MED12-Wt patients in combination with the five WES cohorts. B Multivariate Cox regression analysis of MED12 mutations in WES cohort, the confounding factors including sex, age, metastasis status, treatment, TMB level, and cancer type were adjusted. The proportional hazards assumption was tested before the Cox regression used the Stratified Cox model to resolve independent variables that do not conform to the PH assumption. C Comparison of the ORR between the MED12-Mut and MED12-Wt groups from the WES cohorts. D Comparison of the DCR between the MED12-Mut and MED12-Wt groups from the WES cohorts. E Kaplan–Meier survival analysis comparing OS between MED12-Mut and MED12-Wt patients in the MSKCC cohort. F Multivariate Cox regression analysis of MED12 mutations in the combination of MSKCC cohort with age, sex, metastatic status, treatment type, TMB, and cancer types were taken into account. The proportional hazards assumption was tested before the Cox regression used the Stratified Cox model to resolve independent variables that do not conform to the PH assumption